---

Top Highlights for December 2013:  (Please click on read more to see details)

1. India Inc strikes 480 M&As deal amounting to $27.4 billion during 2013: Grant Thornton. Read more
2. Pieris AG, a Aagami Client inks pact with India’s Stelis Biopharma. Read more
3. British drug maker GSK to increase $2 billion in its Indian subsidiaries.
4. Mylan completes $1.75 billion buyout of Agila from India's Strides Arcolab.
5. Madison Dearborn Partners to acquire Ikaria for $1.6 billion, and planning to expand its acquired business into India, Japan & China. Read more
6. Saudi Basic Industries Corp opens $100 million R&D technology center in India. Read more
7. Korea's Medipost transfers exclusive sales & distribution rights of its stem cell-based cartilage repair drug to India's Alkem Laboratories.
8. US's Kibow Biotech Inc plans to enter India's fast-growing dietary supplement market with Renadyl product. Read more
9. India’s healthcare sector is growing at 15% CAGR and expected to touch $158.2 billion by 2017: Equentis Capital Report. Read more

 

Featured Opportunities and Aagami Updates: (Please click on link to view details)

1. Product Licensing opportunities:

• Co-Development/Partnership opportunity in Oncology and STEMI with an Innate Immune Drug Development Company based in Ireland
• Co-development Opportunity with a US company in innovative Breast cancer vaccine and Prostate cancer vaccine
• Opportunity to Partner on new linker technology which combines Paclitaxel/ Doxorubicin/ Docetaxel with Albumin and make better generic of these drugs which can easily take the 5052b pathway and will be patent protected.

2.Technology Licensing available for:

• Technology to extend plasma half-life (10-100 fold), improve in vivo activity, allow less frequent and lower dosing combined with better patient tolerability
• Innovative Chemotherapy - "Targeted Transferrin Transport Technology”
• The very first NANOTECHNOLOGY based diagnostic platform - future of science in MI

3. Aagami's Business and Market Research Presentation available now on Aagami website.

4. Aagami CEO to participate in J P Morgan 2014 and Biotech Showcase 2014 in San Francisco